PharmaCyte Biotech vs Genenta Science S.p.A.
PMCB and SAEN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PMCB and SAEN compare
PharmaCyte Biotech scores higher on the StockData Score (7 against 6 for Genenta Science S.p.A.), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PMCB | SAEN |
|---|---|---|
| Size and price | ||
| Market cap | $4.3M | – |
| Share price | $0.399 | $0.680 |
| Change, 1 year | −54.7% | −69.1% |
| Change, 5 years | −84.7% | – |
| Beta (5Y) | 0.76 | 0.26 |
| Employees | 2 | 13 |
| StockData Score | ||
| Total score | 7 (better) | 6 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 5 | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.2× | – |
| Growth | ||
| Net income growth (TTM) | −163% | – |
| Profitability | ||
| Return on equity | −48.9% | −38.0% (better) |
| Return on invested capital | −23.5% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 40.30 (better) | 14.16 |
| Altman Z-score | −3.43 | – |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | 9.4% | – |
| Shareholder yield | 9.4% | – |
| Ownership | ||
| Held by institutions | 7.1% | 3.1% |
| Held by insiders | 7.1% | 33.5% |
| Insider net buying, 12 months | $129K | – |
| Short interest, % of float | 0.51% | – |
Go deeper
- PMCB stock overview
- PMCB income statement
- PMCB valuation and score
- SAEN stock overview
- SAEN income statement
- SAEN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.